【摘要】：目的系統(tǒng)評(píng)價(jià)黃連素對(duì)比二甲雙胍治療多囊卵巢綜合征(PCOS)的有效性和安全性。方法計(jì)算機(jī)檢索PUBMED、Cochrane數(shù)據(jù)庫(kù)、中國(guó)知網(wǎng)、維普和萬(wàn)方數(shù)據(jù)平臺(tái)等,從建庫(kù)至2015年2月,選擇黃連素對(duì)比二甲雙胍治療PCOS的隨機(jī)對(duì)照試驗(yàn)(RCT)。按Cochrane系統(tǒng)評(píng)價(jià)方法評(píng)價(jià)質(zhì)量,用Rev Man 5.3軟件進(jìn)行統(tǒng)計(jì)分析。結(jié)果共納入3個(gè)RCT,合計(jì)197例PCOS患者,試驗(yàn)組98例,對(duì)照組99例。Meta分析結(jié)果顯示:黃連素在降低腰臀比、空腹胰島素、總膽固醇及低密度脂蛋白膽固醇水平方面的療效優(yōu)于二甲雙胍,在降低體質(zhì)指數(shù)、空腹血糖、穩(wěn)態(tài)模型評(píng)估胰島素抵抗指數(shù)、三酰甘油、總睪酮水平及升高高密度脂蛋白膽固醇水平方面的療效與二甲雙胍相當(dāng)。結(jié)論相比二甲雙胍,黃連素更適合治療中心性肥胖、空腹胰島素水平明顯升高的胰島素抵抗者、高膽固醇血癥及高低密度脂蛋白膽固醇水平者和不能耐受二甲雙胍胃腸道不良反應(yīng)的PCOS患者。鑒于本系統(tǒng)評(píng)價(jià)納入研究較少且樣本含量較小,因此未來(lái)尚需開展更多大樣本、多中心、設(shè)計(jì)嚴(yán)格的高質(zhì)量RCT加以驗(yàn)證。
[Abstract]:Objective to evaluate the efficacy and safety of berberine versus metformin in the treatment of polycystic ovary syndrome (PCOS). Methods the PUBMED,Cochrane database, China Zhiwang, Weip and Wanfang data platform were searched by computer. From the establishment of the database to February 2015, a randomized controlled trial (RCT).) with berberine versus metformin was used to treat PCOS. According to the evaluation method of Cochrane system, the statistical analysis was carried out with Rev Man 5.3 software. Results A total of 197 cases of PCOS were included in 3 RCT, patients, 98 cases in the trial group and 99 cases in the control group. The results of Meta analysis showed that berberine decreased waist-to-hip ratio, fasting insulin, and insulin, Total cholesterol and low density lipoprotein cholesterol levels were superior to metformin in lowering body mass index, fasting blood glucose, homeostasis model to evaluate insulin resistance index, triacylglycerol. The effects of total testosterone and elevated high density lipoprotein cholesterol were comparable to metformin. Conclusion compared with metformin, berberine is more suitable for the treatment of insulin resistance patients with central obesity and elevated fasting insulin level. Patients with hypercholesterolemia and high and low density lipoprotein cholesterol levels and PCOS patients who could not tolerate the adverse reactions of metformin gastrointestinal tract. In view of the small number of samples and the small number of samples, it is necessary to carry out more large samples, multi-center and strict design of high quality RCT to verify the system evaluation in the future.
【作者單位】： 中山大學(xué)附屬第六醫(yī)院婦科;
【分類號(hào)】：R711.75

【參考文獻(xiàn)】

相關(guān)碩士學(xué)位論文 前1條

1 鄺Y，

本文編號(hào)：2298184